Amarillo National Bank Has $404,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Amarillo National Bank lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.8% during the 4th quarter, HoldingsChannel reports. The firm owned 15,235 shares of the biopharmaceutical company’s stock after selling 943 shares during the quarter. Amarillo National Bank’s holdings in Pfizer were worth $404,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Creative Planning grew its holdings in Pfizer by 17.1% during the third quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after purchasing an additional 266,167 shares during the last quarter. Swedbank AB grew its stake in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the last quarter. Bleakley Financial Group LLC grew its stake in shares of Pfizer by 2.7% in the third quarter. Bleakley Financial Group LLC now owns 109,428 shares of the biopharmaceutical company’s stock worth $3,167,000 after acquiring an additional 2,914 shares during the last quarter. Aaron Wealth Advisors LLC grew its stake in shares of Pfizer by 41.7% in the third quarter. Aaron Wealth Advisors LLC now owns 16,576 shares of the biopharmaceutical company’s stock worth $480,000 after acquiring an additional 4,878 shares during the last quarter. Finally, Richard W. Paul & Associates LLC grew its stake in shares of Pfizer by 1.6% in the third quarter. Richard W. Paul & Associates LLC now owns 31,692 shares of the biopharmaceutical company’s stock worth $917,000 after acquiring an additional 494 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Guggenheim restated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $25.50 on Friday. The stock has a 50-day simple moving average of $26.28 and a 200 day simple moving average of $27.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The stock has a market capitalization of $144.48 billion, a price-to-earnings ratio of 18.08, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the business posted $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.75%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is currently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.